BRAF and malignant colon neoplasm: Meanwhile, the randomized phase 2/3 study A022004 aims to treat patients with encorafenib and cetuximab versus usual care in the adjuvant setting for patients with stage 2B and stage 3 colon cancer (CC) with BRAF V600E [22].